You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol » Stages of illness and recovery
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
Next revisionBoth sides next revision
home:mp:stages [07.18.2015] – [Stage 2: Unhealthy VDR, pathogens downregulate immune activity] joyfulhome:mp:stages [12.14.2018] – [Stage 1: Healthy Vitamin D Receptor (VDR), low pathogen load] sallieq
Line 9: Line 9:
  
  
-=====Stage 1: Healthy Vitamin D Receptor (VDR), low pathogen load =====+=====  Prior to immune dysfunction =====
  
 In a healthy human, the body can carefully regulate activity of the VDR, which it does by controlling the concentrations of two key forms of vitamin D: 25-D and 1,25-D. Both molecules are attracted to the Receptor and bind to it for hours at a time, after which they drop off. The essential difference between the key molecules is that when 1,25-D docks to the VDR, it turns the Receptor on; when 25-D docks to the VDR, it is turned off. When it becomes necessary to turn on the VDR, the body increases production of 1,25-D. Conversely, when an active VDR is no longer necessary, the body converts 1,25-D into 25-D. In healthy humans, this control mechanism works well. For example, in the event a pathogen is noticed, the body increases production of 1,25-D, which in turn increases activity of the VDR. In a healthy human, the body can carefully regulate activity of the VDR, which it does by controlling the concentrations of two key forms of vitamin D: 25-D and 1,25-D. Both molecules are attracted to the Receptor and bind to it for hours at a time, after which they drop off. The essential difference between the key molecules is that when 1,25-D docks to the VDR, it turns the Receptor on; when 25-D docks to the VDR, it is turned off. When it becomes necessary to turn on the VDR, the body increases production of 1,25-D. Conversely, when an active VDR is no longer necessary, the body converts 1,25-D into 25-D. In healthy humans, this control mechanism works well. For example, in the event a pathogen is noticed, the body increases production of 1,25-D, which in turn increases activity of the VDR.
Line 20: Line 20:
 The body responds by increasing production of 1,25-D. While some 1,25-D activates the VDR, a lot does not, because the VDR is blocked by bacterial ligands and the body is never able to completely out-compete the production of bacterial substances. The body responds by increasing production of 1,25-D. While some 1,25-D activates the VDR, a lot does not, because the VDR is blocked by bacterial ligands and the body is never able to completely out-compete the production of bacterial substances.
  
-The increase in 1,25-D introduces a new problem entirely. When 1,25-D reaches higher and higher levels, it begins to interfere with the activity of important nuclear receptors other than the VDR. While 1,25-D is the activating hormone for the VDR, at high enough levels it binds to and inactivates other receptors. Like the VDR, these receptors have a role in innate immune function, but they also transcribe genes that lead to production of hormones of their own such as thyroid hormones and the sex hormones. This is why high levels of 1,25-D can lead to low levels of other hormones.+The increase in 1,25-D introduces a new problem entirely. When 1,25-D reaches higher and higher levels, it begins to interfere with important activities of other nuclear receptors. While 1,25-D is the activating hormone for the VDR, at high enough levels it binds to and inactivates other receptors. Like the VDR, these receptors have a role in innate immune function, but they also transcribe genes that lead to production of hormones of their own such as thyroid hormones and the sex hormones. This is why high levels of 1,25-D can lead to low levels of other hormones.
  
  
Line 57: Line 57:
  
  
-{{tag>Simple_Explanations Starting_the_Marshall_Protocol}}+{{tag>MP Simple_Explanations Starting_the_Marshall_Protocol}}
  
  
home/mp/stages.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.